TITLE

Improvement of Walking Distance in Patients with Intermittent Claudication by Chronic Local Therapy with Isosorbide Dinitrate Ointment

AUTHOR(S)
Testa, Roberto; Biagini, Andrea; Michelassi, Claudio; Emdin, Michele; Mazzei, Maria Giovanna; Carpeggiani, Clara; L'Abatte, Antonio
PUB. DATE
January 1988
SOURCE
Angiology;Jan1988 Part 1, Vol. 39 Issue 1, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Isosorbide dinitrate ointment (100 mg tid) was directly applied to 30 male patients with stable, documented intermittent claudication on the areas where ischemic pain was experienced. The symptom-free distance walked (DWA) and the maximum distance reached (MDR) basally, after one, three, six, and twelve months were evaluated by means of treadmill stress tests (TSTs) (angle 0°-velocity constant/patient). After the basal TST, patients were randomly divided into two groups: placebo group and therapy group (double blind), and a further TST was administered one month later. DWA results were 74±8 m vs 297±83 m and MDR results were 163 ± 22 m vs 506±86 m in the therapy group (basal vs one month TST: p <.01) and 94±24 m vs 96 ± 15 m and 232 ± 53 m vs 183 ± 26 m in the placebo group, respectively (basal vs one month TST:NS). Being confident that a significant placebo effect was absent, the authors opened the trial and treated all patients, repeating further TSTs at three, six, and twelve months. The following results were obtained: DWA was 84±13 m, 316 ± 63 m, 374 ± 55 m, and 452±61 m; and MDR was 197 ± 29 m, 431 ± 59 m, 514 ± 57 m, and 547 ± 59 m, respectively, in basal conditions and after three, six, and twelve months of treatment (p <.01 for all the values for both DWA and MDR vs basal values). These results suggest the effectiveness of this treatment, independently from a placebo effect, in improving walking tolerance in patients with intermittent claudication.
ACCESSION #
16352785

 

Related Articles

  • Treatment of intermittent claudication. Karthikeyan, G.; Eikelboom, John W. // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;3/21/2009, p671 

    The authors reflect on methods which are used to treat intermittent claudication. They suggest that any methods that are used should improve the patient's symptoms and decrease the risk of cardiovascular problems. They argue that the most important goal of medical treatment in patients with...

  • Methylprednisolone/sodium chloride.  // Reactions Weekly;11/29/2008, Issue 1230, p26 

    The article presents a case study of a 62-year-old man who had a reaction to the administration of methylprednisolone in saline solution. The patient reported leg pain and weakness after the first bolus. The condition returned to baseline after the therapy was discontinued. The condition...

  • Placebo-Controlled Trial of Ketanserin in the Treatment of Intermittent Claudication. Cameron, H. A.; Waller, P. C.; Ramsay, L. E. // Angiology;Jul1987, Vol. 38 Issue 7, p549 

    The effect of ketanserin on the symptoms of 21 patients with stable intermittent claudication was examined in a double-blind, placebo-controlled, parallel-group study. Benefit was assessed by repeated treadmill exercise tests, recording claudication and total walking times. After three months'...

  • INTERMITTENT CLAUDICATION. Siggaard-Andersen, J.; Petersen, F. Bonde // Angiology;Jul1968, Vol. 19 Issue 7, p426 

    The walking distance in 155 patients with intermittent claudication was measured on a treadmill at various speeds and angles of inclination. The results were compared with the claudication distances noted in the patients' histories. No correlation was found between the two values. It is...

  • Reliability of Walking Endurance with an Incremental Treadmill Test. Kirby, R. Lee; Marlow, Ronald W. // Angiology;Jul1987, Vol. 38 Issue 7, p524 

    Treadmill walking endurance is the major outcome measure for intervention studies on patients with intermittent claudication. The measurement properties of this test have not, however, been well documented. We assessed the test-retest reliability of treadmill walking endurance in 10 normal...

  • Functional claudication distance: a reliable and valid measurement to assess functional limitation in patients with intermittent claudication. Kruidenier, Lotte M.; Nicolaï, Saskia P. A.; Willigendael, Edith M.; de Bie, Rob A.; Prins, Martin H.; Teijink, Joep A. W. // BMC Cardiovascular Disorders;2009, Vol. 9, Special section p1 

    Background: Disease severity and functional impairment in patients with intermittent claudication is usually quantified by the measurement of pain-free walking distance (intermittent claudication distance, ICD) and maximal walking distance (absolute claudication distance, ACD). However, the...

  • Peripheral arterial disease symptom subtype and walking impairment. Collins, Tracie C.; Petersen, Nancy J.; Suarez-Almazor, Maria // Vascular Medicine;2005, Vol. 10 Issue 3, p177 

    Walking impairment is common in patients with peripheral arterial disease (PAD). The purpose of this study was to compare specific leg symptoms and walking impairment in a racially diverse cohort of patients with PAD. Patients who were receiving care at the Michael E DeBakey Veterans Affairs...

  • Effects of Pentoxifylline on Severe Intermittent Claudication. Reich, Theobald; Gilings, Dennis // Angiology;Sep1987, Vol. 38 Issue 9, p651 

    Pentoxifylline has been shown to improve treadmill walking distances under blinded, controlled conditions in patients with intermittent claudication. From the pooled data of a blinded, controlled, randomized, multicenter trial, the data from all enrolled patients with severe claudication (< 70 m...

  • Comparison of Safety and Efficacy of Buflomedil and Naftidrofuryl in the Treatment of Intermittent Claudication. Rosas, Guillermo; Cerdeyra, Cristina; Lucas, Miguel A.; Parano, Jorge R.; Villa, Juan J. // Angiology;May1981, Vol. 32 Issue 5, p291 

    In a group of 58 patients with peripheral arteriopathies, we have studied efficacy and safety of buflomedil hydrochloride and naftidrofuryl. Both drugs have been shown to have vasoactive properties evaluated through walking capacity and time of hyperemia. According to our results, buflomedil is...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics